Director Tong Chunrong: Why MICM Integrated Diagnosis Is Mandatory for Hematological Malignancies
- Elva Chen
- 3 days ago
- 4 min read
MICM integrated diagnosis covers Morphology (M), Immunology (I), Cytogenetics (C) and Molecular biology (M), serving as the core diagnostic system for hematological malignancies. Its updated scope also incorporates two additional P modules: Pathogen detection and Pharmacogenomics (MICM-PP). Director Tong Chunrong from Beijing Boren Hospital elaborates on how this integrated system enables precise subtyping and individualized therapy for blood cancers.
I. Distinction Between Laboratory Diagnosis and Clinical Diagnosis
Many patients mistake a single lab report for a confirmed diagnosis. A complete clinical diagnosis requires comprehensive integration of lab results, medical history, family history, medication exposure and contact records.
Clinical Case Examples
Elevated white blood cells lasting a decade usually points to chronic leukemia, while a surge over only a few days strongly suggests acute leukemia. Medical history directly shapes treatment plans.
Secondary therapy-related leukemia may develop in patients with prior malignancies treated with chemo/radiotherapy, who are often recommended for allogeneic stem cell transplantation.
Family history reveals genetic susceptibility: inherited predispositions combined with external triggers drive cancer onset, just as multiple family members may suffer from hypertension, diabetes or tumors.
Long-term exposure to toxic substances destabilizes chromosomes and induces gene mutations; such patients rarely respond well to medication and often require transplantation.
Infectious exposure history matters too: Adult T-cell leukemia/lymphoma is virus-induced and endemic in coastal regions of Japan and Fujian, China. Neglecting exposure clues delays targeted testing.
Lab workups including blood routine, bone marrow examination and imaging are essential, with MICM-PP integrated testing as the gold standard for blood tumors.
What Is MICM?
MICM is a modern comprehensive classification framework combining four layers of testing to identify disease nature from cellular appearance, immune markers, chromosomes and genes:
M (Morphology): Microscopic cell observation, cytochemical staining and tissue pathology
I (Immunology): Flow cytometry and immunohistochemistry to identify cellular lineage; optional immunoglobulin quantification/electrophoresis
C (Cytogenetics): Karyotyping and FISH to detect chromosomal numerical/structural abnormalities
M (Molecular biology): Fusion gene screening/quantification, germline & tumor gene mutation testing, copy number analysis, IgH/TCR clonality assay, pathogen gene detection and post-transplant chimerism monitoring
Combined MICM data allows accurate risk stratification, relapse prediction and targeted drug selection for personalized precision care.
What Is MICM-PP?
Built on classic MICM, two supplementary P modules optimize individualized treatment:
Pathogen testing: Detect pathogens such as EBV and Helicobacter pylori via gene and tissue assays
Pharmacogenomics & therapeutic drug monitoring: Adjust drug dosages by measuring in-vivo drug concentrations and analyzing drug-metabolizing genes for safer, more accurate treatment
A definitive diagnosis cannot rely on one single report. Full integration of morphological, immunological, cytogenetic, molecular, pathogen and pharmacological data generates clear clinical conclusions and tailored regimens. Diagnoses are dynamically revised throughout treatment based on patient response and follow-up results.
II. Core Purposes of MICM Integrated Diagnosis
Blood cancer treatments fall into transplant and non-transplant categories. Transplants include autologous and allogeneic types; non-transplant options cover chemotherapy, targeted therapy, immunotherapy and hypomethylating agents. MICM results determine the optimal treatment pathway.
1. Transplant Eligibility & Transplant Type Selection
Transplant necessity and type hinge on risk stratification derived from MICM data. Autologous transplantation uses the patient’s own stem cells, yet poor efficacy occurs with germline susceptibility genes or chemotherapy-damaged stem cells, requiring allogeneic transplantation instead. This explains why germline susceptibility screening is critical for treatment planning.
2. Non-Transplant Therapeutic Options
Surgery: Rarely used for systemic hematological tumors, only to relieve compression from large tumor masses
Chemotherapy: Not universally effective; patients with monosomy 7 typically show poor response
Targeted therapy: Gene variants determine matching targeted agents
Immunotherapy (CAR-T, antibody drugs): Dependent on surface antigens like CD19 for eligible patients
3. Hierarchical Treatment Goals
Primary goal: Clinical cure
For acute leukemia, sustained MRD negativity for 3+ years brings relapse risk below 5%; 5+ years reduces risk under 1%, defined as clinical cure. Most acute leukemias are curable.
Secondary goal: Prolong survival if cure is unattainable
Tertiary goal: Alleviate symptoms and improve quality of life for end-stage patients
MICM results answer all key clinical questions: transplant timing, medication combinations, dosage adjustment and therapeutic target setting.
III. Real Clinical Case Demonstrating Integrated Diagnosis Value
A 47-year-old patient presented with fever, fatigue and skin petechiae for 17 days, with a white blood cell count of 61×10⁹/L. Local lab smears showed sporadic immature monocytes, and bone marrow contained 65% blasts plus immature monocytes. Morphology suggested acute monocytic leukemia, and flow cytometry confirmed acute myeloid leukemia (AML).
Gene testing uncovered multiple pathogenic mutations: DNMT3A, NPM1, IDH1, JAK2. These molecular findings reshaped clinical decisions in four key ways:
Risk re-stratification: Normal karyotype would conventionally classify the patient as intermediate-risk, yet concurrent multiple mutations indicated poor prognosis. Persistent DNMT3A clones (29% variant frequency) post-remission revealed pre-existing mutant hematopoietic stem cells, carrying high relapse and secondary malignancy risk. The patient was reclassified as high-risk.
Targeted medication guidance: DNMT3A mutations respond to hypomethylating agents (decitabine, azacitidine); NPM1 pairs with ATRA; JAK2 matches JAK inhibitors such as ruxolitinib; IDH variants have corresponding targeted inhibitors. The initial regimen combined decitabine + venetoclax plus supplementary targeted agents.
Transplant indication: Intermediate-risk AML has less than 40% cure rate with chemotherapy alone. Risk factors including hyperleukocytosis at onset, multiple adverse gene mutations and persistent DNMT3A clones mandated allogeneic hematopoietic stem cell transplantation post-complete remission, followed by maintenance targeted therapy to prevent relapse.
Long-term monitoring strategy: NPM1 serves as a cost-effective, sensitive quantitative PCR biomarker, combined with flow cytometry MRD surveillance and deep sequencing of other mutant genes for dynamic efficacy tracking.
Key Takeaway of the Case
Morphology identifies leukemia subtype; flow cytometry confirms myeloid monocytic lineage; karyotyping shows normal intermediate-risk chromosomes; molecular testing uncovers high-risk features, druggable targets and monitoring markers, indicating urgent transplant.
Conclusion
Many family members worry about excessive testing, yet every MICM assay delivers unique diagnostic clues. Each test is one puzzle piece; only integrated analysis reveals the full picture of disease subtype, risk level and treatment roadmap. Treatment plans are data-driven rather than experience-based. Integrated diagnosis streamlines precision care and boosts clinical confidence in every therapeutic step.
Disclaimer: Expert opinions are for reference only; all treatment decisions must be discussed with your attending physician.
Comments